



**Media Releases » Torrent Pharma records 44% growth in operating profit in Q4 FY12; declares dividend of Rs 2.50 p.s.**  
*May 18th, 2012*

Ahmedabad-based Torrent Pharmaceuticals Limited, today released its financial results for the fourth quarter ended 31st March, 2012. The Q4 revenues stood at Rs. 674 crores, up by 32% from Rs. 511 crores in the comparable quarter of last year. The company declared a final dividend of Rs 2.50 per share taking the total dividend for the year to Rs 8.50 per share.

During Q4, domestic formulation business recorded revenues of Rs. 200 crores, growing by 10% with a relatively low performance in the acute therapy segment. International revenues grew by 47% to Rs. 394 crores supported by healthy growth in Brazil and US operations. Operating profits (PBDIT) before exceptional items for the quarter stood at Rs. 67 crores showing a growth of 44%. Net profit before exceptional items for the quarter grew by 22% to Rs. 52.2 crores compared to Rs. 42.8 crores during the same period last year.

Exceptional item during the quarter of Rs. 65 crores represents provision for estimated future sales returns from the market. During the quarter the Company has effected a change in method of estimating the provisioning requirement of sales returns resulting into a onetime provision. As per trade practice, the Company accepts sales returns which are primarily on account of goods whose shelf life have expired or about to expire.

For FY 11-12, the revenues increased by 23% to Rs. 2696 crores compared with Rs. 2,198 crores for the corresponding period last year. For FY 11-12, the PBDIT grew by 29% to Rs. 501 crores while the Net Profit before exceptional items, grew by 25% to Rs. 338 crores.

Investments in product development are being made to support the build-up of the Brazil, Europe and US operations. The total revenue expenditure for FY 2011-12 on R&D was 5% of consolidated net sales and operating income.

About Torrent Pharma: Torrent Pharma, with an annual turnover of over Rs. 2,650 crores is the flagship company of the Torrent Group. With many of its products ranking among the Top 200 brands, Torrent continues to be at the forefront of the Indian pharmaceutical industry through research, innovation and breakthrough discoveries in the therapeutics areas of Diabetology, Cardiovascular, Central Nervous System, Gastro-Intestinal, Anti-infective, Pain management and Gynecology. Its Research Center employs over 640 scientists in the areas of drug discovery and development. Currently, Torrent has various discovery projects in pipeline. It has filed 450 patents for NCE's in all major markets worldwide, of which 211 patents have been granted so far. Torrent's manufacturing plant at Chatral has a capacity to manufacture approx. 5,500 million Tablets, capsules and vials and 45,000 kgs of Bulk Drugs/API. The facility has already been approved by authorities from regulated markets like US, UK, Germany, Australia and South Africa. The manufacturing plant at Baddi has a capacity to manufacture 3,000 million tablets and capsules. The company recently commissioned a new manufacturing plant at Sikkim having capacity to manufacture 3,900 million tablets per annum.